Patrys Limited · ASX:PAB
Patrys — Shareholder Meeting (November 2009)
16 slides from Patrys's shareholder meeting presentation, Nov 27, 2009
Slide 1: Developing More Effective and Safer Treatments for Cancer
For personal use only ASX: PAB ASX: PAB Developing More Effective and Safer Treatments for Cancer Annual General Meeting 27 November 2009 Chief Executive Officer Presentation Daniel Devine
Slide 2: Overview
Overview For personal use only Objective Develop safer and more effective treatments for cancer Lead Products PAT-SM6, PAT-LM1, PAT-SC1 – multiple cancer indications Pipeline Deep pipeline of additional products and disease targets Listing ASX (Jul 2007): PAB Headquarters Melbourne R&D Locations Mel
Slide 3: Targeted Indications
Targeted Indications For personal use only Five year mortality rate for targeted cancers Little increase in survival (U.S National Cancer Institute) over past 20 years 100 90 Most treatments have 80 significant adverse side Percent mortality rates 70 effects 60 50 Despite lack of potency 40 and safe
Slide 4: Milestones Achieved
Milestones Achieved For personal use only Leads effective in animal models of colon & gastric cancer metastases Nov 2008 Accepted to present at leading industry R&D conferences in USA Nov 2008 Stronger financial Acquire Acceptys, Inc.; injection of $3.1m at premium to market Dec 2008 position Allian
Slide 5: Product Pipeline
Product Pipeline For personal use only Discovery Lead Selection Preclinical Clinical PAT-SC1 PAT-SC1 IgM: Cancer 2009: Acquired clinical product 2010: Scale-up manufacturing PAT-LM1 IgM: Cancer 2011: Broaden clinical trials PAT-SM6 IgM: Cancer PAT-LM1 and PAT-SM6 2009: Completed preclinical develop.
Slide 6: PAT-SC1 Lead Candidate
PAT-SC1 Lead Candidate For personal use only Patient Survival Significantly higher survival 100% Effective rate for treated gastric cancer patients 90% Safe Well tolerated 80% Dose < 10% of marketed anti- 70% Low dose cancer antibodies 60% Proof of Provides POC for other lead 50% concept products Re
Slide 7: PAT-SM6 Lead Candidate
PAT-SM6 Lead Candidate For personal use only PAT-SM6: Unique LDL Mediated Potent anti-cancer activity in Cancer Cell Killing Mechanism Effective animal studies of primary tumours and metastases Application to >98% of Specificity patients across many cancers Successful completion of Pre-clinical prec
Slide 8: PAT-LM1 Lead Candidate
PAT-LM1 Lead Candidate For personal use only PAT-LM1 Effective Against Lung Cancer Potent anti-cancer activity in Tumours Effective animal studies of primary tumours and metastases Application to >90% of Indications patients across many cancers Successful completion of Pre-clinical preclinical devel
Slide 9: Product Advantages
Product Advantages For personal use only Current Cancer Patrys’ Natural Human Factor Treatments Antibodies Interfere with healthy Activity of drug very cancer- Safer cells and tissues specific; very safe profile Primary cancer Often effective only at Potentially effective against and metastases prim
Slide 10: Proprietary Targets
Proprietary Targets For personal use only Biotech has focused on developing Disease 2nd Gen. “optimised” drugs to established targets Drug Target Products in Clinic Result is a log jam of second generation products to the same targets Target/Marketed Antibodies CD20 Rituxan 10 Drug optimisation tech
Slide 11: Patent Portfolio
Patent Portfolio For personal use only Priority Broad protection of Family Description of Claims Date PAT-SC1 1998 CD55 disease target drugs, disease targets, PAT-PA1 2001 CFR-1 disease target and manufacturing PAT-CM1 2002 PAT-CM1 antibodies and uses thereof PAT-LM1 2003 PAT-LM1 and uses thereof PA
Slide 12: Research Results
Research Results For personal use only Product Characteristics 2009 Research: Binds to 88% of tumours screened 3 new patent families created; now No binding to healthy tissues screened 18 patent families in total PAT-BA1 Kills melanoma and gastric cancer Four new promising product cells candidates a
Slide 13: External Opportunities
External Opportunities For personal use only Combining internal programs with prudent acquisitions accelerates value faster and at reduced costs & risks Quality US, European and Australasian assets available at very discounted values - 32% of public biotechs trade below cash! Good clinical stage ass
Slide 14: Objectives
24 Month Objectives For personal use only Research Clinical Patents Bus Dev 7 new patent families 3 new lead PAT-SM6 clinical Seek acquisitions of to cover new products data synergistic assets products and targets (CY2010–2011) (1HCY2010) (CY2010) (CY2010–2011) 4 new disease PAT-LM1 clinical Prosecu
Slide 15: Value Proposition
Value Proposition For personal use only Patrys Share Price (ASX) Recent advances only partially reflected in value (< 20% of pre- GFC level) Trading volume have reached > 5X volume in March ’09 Major milestones to come as Patrys becomes clinical stage company ‘07 to ‘09 Antibody Deal Values US $ Mil
Slide 16: Summary
Summary For personal use only Strong competitive position in fastest growing biotechnology segment Diverse and multiple commercial opportunities offers “portfolio” investment; expanding pipeline Moving from preclinical to clinical status for internal programs – largest value appreciation in biotech